These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3753162)

  • 1. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy.
    van Kammen DP; van Kammen WB; Mann LS; Seppala T; Linnoila M
    Arch Gen Psychiatry; 1986 Oct; 43(10):978-83. PubMed ID: 3753162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment.
    Frecska E; Perényi A; Bagdy G; Révai K
    Psychiatry Res; 1985 Nov; 16(3):221-6. PubMed ID: 2868474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy.
    van Kammen DP; Mann LS; Sternberg DE; Scheinin M; Ninan PT; Marder SR; van Kammen WB; Rieder RO; Linnoila M
    Science; 1983 May; 220(4600):974-7. PubMed ID: 6133351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid.
    Doran AR; Boronow J; Weinberger DR; Wolkowitz OM; Breier A; Pickar D
    Neuropsychopharmacology; 1987 Dec; 1(1):25-32. PubMed ID: 3509912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
    Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
    Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrophy limited to the third ventricle in chronic schizophrenic patients. Report of a controlled series.
    Boronow J; Pickar D; Ninan PT; Roy A; Hommer D; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1985 Mar; 42(3):266-71. PubMed ID: 2579616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.
    Maas JW; Bowden CL; Miller AL; Javors MA; Funderburg LG; Berman N; Weintraub ST
    Schizophr Bull; 1997; 23(1):147-54. PubMed ID: 9050120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion.
    Davis KL; Faull KF; Hollister LE; Barchas JD; Berger PA
    Psychopharmacology (Berl); 1981; 72(2):155-60. PubMed ID: 6782605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of monoamine indices in patients with chronic schizophrenia.
    Frecska E; Bagdy G; Perenyi A; Arato M; Degrell I; Mogyorosy Z
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):291-5. PubMed ID: 2577713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid HVA, central brain atrophy, and clinical state in schizophrenia.
    Houston JP; Maas JW; Bowden CL; Contreras SA; McIntyre KL; Javors MA
    Psychiatry Res; 1986 Nov; 19(3):207-14. PubMed ID: 3797547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
    Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
    J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients.
    Rimón R; Roos BE; Kampman R; Hyyppä S; Ranta P; Myllylä V
    Ann Clin Res; 1979 Feb; 11(1):25-9. PubMed ID: 453776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on dopamine metabolite in cerebrospinal fluid of schizophrenics and epilepsics].
    Jiang S; Chen X; Liao W
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(2):155-6. PubMed ID: 10681831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine metabolites in rat cisternal cerebrospinal fluid: major contribution from extrastriatal dopamine neurones.
    Hutson PH; Curzon G
    J Neurochem; 1986 Jan; 46(1):186-90. PubMed ID: 2415677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations in human lumbar cerebrospinal fluid.
    Ebinger G; Michotte Y; Herregodts P
    J Neurochem; 1987 Jun; 48(6):1725-9. PubMed ID: 3572399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat.
    Mignot E; Laude D; Elghozi JL
    J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An association between increased concentrations of cerebrospinal fluid dopamine sulfate and higher negative symptom scores in patients with schizophrenia and schizoaffective disorder.
    Risby ED; Jewart RD; Lewine RR; Risch SC; Stipetic M; McDaniel JS; Caudle J
    Biol Psychiatry; 1993 Nov; 34(9):661-4. PubMed ID: 8292696
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative analysis of indices of central dopaminergic functions in man.
    Bagdy G; Arató M; Baraczka K; Fekete MI
    Life Sci; 1983 Jun; 32(23):2667-76. PubMed ID: 6855463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.
    van Kammen DP; Peters J; van Kammen WB
    Psychiatr Clin North Am; 1986 Mar; 9(1):81-97. PubMed ID: 2421272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-Dihydroxyphenylethylamine and 5-hydroxytryptamine metabolism in the rat: acidic metabolites in cisternal cerebrospinal fluid before and after giving probenecid.
    Curzon G; Hutson PH; Kantamaneni BD; Sahakian BJ; Sarna GS
    J Neurochem; 1985 Aug; 45(2):508-13. PubMed ID: 2409231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.